{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T16:46:29Z","timestamp":1783183589501,"version":"3.54.6"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Microbial Pathogenesis"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.micpath.2023.106356","type":"journal-article","created":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T07:58:10Z","timestamp":1695542290000},"page":"106356","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Antibiotics and nano-antibiotics in treatment of lung infection: In management of COVID-19"],"prefix":"10.1016","volume":"184","author":[{"given":"Sushant","family":"Sunder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kriti","family":"Bhandari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Sounkaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjari","family":"Vyas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhupendra Pratap","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8736-7993","authenticated-orcid":false,"given":"Prakash","family":"Chandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.micpath.2023.106356_bib1","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/22221751.2020.1719902","article-title":"Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan","volume":"9","author":"Chan","year":"2020","journal-title":"Emerg. Microb. Infect."},{"key":"10.1016\/j.micpath.2023.106356_bib2","series-title":"Insights into Cross-species Evolution of Novel Human Coronavirus 2019-nCoV and Defining Immune Determinants for Vaccine Development","author":"Ramaiah","year":"2020"},{"key":"10.1016\/j.micpath.2023.106356_bib3","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.chom.2020.02.001","article-title":"Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China","volume":"27","author":"Wu","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.micpath.2023.106356_bib4","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.mib.2016.11.003","article-title":"Viral\u2013bacterial co-infections in the respiratory tract","volume":"35","author":"Bakaletz","year":"2017","journal-title":"Curr. Opin. Microbiol."},{"key":"10.1016\/j.micpath.2023.106356_bib5","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1002\/iub.2356","article-title":"Bacterial co-infections with SARS-CoV-2","volume":"72","author":"Mirzaei","year":"2020","journal-title":"IUBMB Life"},{"key":"10.1016\/j.micpath.2023.106356_bib6","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.cmi.2020.07.041","article-title":"Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study","volume":"27","author":"Garcia-Vidal","year":"2021","journal-title":"Clin. Microbiol. Infection"},{"key":"10.1016\/j.micpath.2023.106356_bib7","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/j.cmi.2020.07.016","article-title":"Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis","volume":"26","author":"Langford","year":"2020","journal-title":"Clin. Microbiol. Infection"},{"key":"10.1016\/j.micpath.2023.106356_bib8","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13756-020-00819-1","article-title":"Etiology and antimicrobial resistance of secondary bacterial infections in patients hospitalized with COVID-19 in Wuhan, China: a retrospective analysis","volume":"9","author":"Li","year":"2020","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"10.1016\/j.micpath.2023.106356_bib9","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.micpath.2023.106356_bib10","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.cmi.2020.04.024","article-title":"COVID-19: don\u2019t neglect antimicrobial stewardship principles","volume":"26","author":"Huttner","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.micpath.2023.106356_bib11","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/S2666-5247(20)30009-4","article-title":"Co-infections: potentially lethal and unexplored in COVID-19","volume":"1","author":"Cox","year":"2020","journal-title":"The Lancet Microbe"},{"key":"10.1016\/j.micpath.2023.106356_bib12","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jiph.2021.02.001","article-title":"Antibiotics in treatment of COVID-19 complications: a review of frequency, indications, and efficacy","volume":"14","author":"Chedid","year":"2021","journal-title":"J. Infect. Public Health"},{"key":"10.1016\/j.micpath.2023.106356_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.107157","article-title":"Clinical characteristics and antibiotics treatment in suspected bacterial infection patients with COVID-19","volume":"90","author":"Liu","year":"2021","journal-title":"Int. Immunopharm."},{"key":"10.1016\/j.micpath.2023.106356_bib14","series-title":"StatPearls","author":"Regunath","year":"2021"},{"key":"10.1016\/j.micpath.2023.106356_bib15","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1469-0691.2006.01393.x","article-title":"The atypical pneumonias: clinical diagnosis and importance","volume":"12","author":"Cunha","year":"2006","journal-title":"Clin. Microbiol. Infection"},{"key":"10.1016\/j.micpath.2023.106356_bib16","doi-asserted-by":"crossref","first-page":"87","DOI":"10.18773\/austprescr.2015.030","article-title":"Prescribing azithromycin","volume":"38","author":"McMullan","year":"2015","journal-title":"Aust. Prescr."},{"key":"10.1016\/j.micpath.2023.106356_bib17","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.tibs.2018.06.011","article-title":"How macrolide antibiotics work","volume":"43","author":"V\u00e1zquez-Laslop","year":"2018","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.micpath.2023.106356_bib18","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1111\/bph.13936","article-title":"The macrolide antibiotic renaissance","volume":"174","author":"Dinos","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.micpath.2023.106356_bib19","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1021\/acs.est.6b06474","article-title":"Urinary antibiotics of pregnant women in eastern China and cumulative health risk assessment","volume":"51","author":"Wang","year":"2017","journal-title":"Environ. Sci. Technol."},{"key":"10.1016\/j.micpath.2023.106356_bib20","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/14787210.2020.1813024","article-title":"Azithromycin in the treatment of COVID-19: a review","volume":"19","author":"Echeverr\u00eda-Esnal","year":"2021","journal-title":"Expert Rev. Anti-infect. Ther."},{"key":"10.1016\/j.micpath.2023.106356_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2020.104228","article-title":"In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect","volume":"145","author":"Andreani","year":"2020","journal-title":"Microb. Pathog."},{"key":"10.1016\/j.micpath.2023.106356_bib22","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3390\/antibiotics5030028","article-title":"The membrane steps of bacterial cell wall synthesis as antibiotic targets","volume":"5","author":"Liu","year":"2016","journal-title":"Antibiotics"},{"key":"10.1016\/j.micpath.2023.106356_bib23","series-title":"StatPearls","author":"Pandey","year":"2021"},{"key":"10.1016\/j.micpath.2023.106356_bib24","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.1080\/07391102.2020.1777904","article-title":"Repurposing cefuroxime for treatment of COVID-19: a scoping review of in silico studies","volume":"39","author":"Durojaiye","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.micpath.2023.106356_bib25","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0213-005X(12)70081-2","article-title":"Multidrug-resistant bacterial infection in solid organ transplant recipients","volume":"30","author":"Cervera","year":"2012","journal-title":"Enferm. Infecc. Microbiol. Cl\u00edn."},{"key":"10.1016\/j.micpath.2023.106356_bib26","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jgar.2018.08.016","article-title":"Antimicrobial-resistant CC17 Enterococcus faecium: the past, the present and the future","volume":"16","author":"Lee","year":"2019","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"10.1016\/j.micpath.2023.106356_bib27","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1097\/FTD.0000000000000562","article-title":"Validation of a Nomogram for achieving target trough concentration of vancomycin: accuracy in patients with augmented renal function","volume":"40","author":"Ishii","year":"2018","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.micpath.2023.106356_bib28","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13756-018-0394-1","article-title":"Hospital acquired vancomycin resistant enterococci in surgical intensive care patients \u2013 a prospective longitudinal study","volume":"7","author":"Kampmeier","year":"2018","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"10.1016\/j.micpath.2023.106356_bib29","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.420","article-title":"Vancomycin therapeutic drug monitoring and population pharmacokinetic models in special patient subpopulations","volume":"6","author":"Monteiro","year":"2018","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.micpath.2023.106356_bib30","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1056\/NEJMcpc2002418","article-title":"Case 17-2020: a 68-year-old man with covid-19 and acute kidney injury","volume":"382","author":"Sise","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.micpath.2023.106356_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105944","article-title":"Teicoplanin: an alternative drug for the treatment of COVID-19?","volume":"55","author":"Baron","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.micpath.2023.106356_bib32","series-title":"StatPearls","author":"Podder","year":"2021"},{"key":"10.1016\/j.micpath.2023.106356_bib33","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12941-021-00444-9","article-title":"Repurposing of antibiotics for clinical management of COVID-19: a narrative review","volume":"20","author":"Yacouba","year":"2021","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"10.1016\/j.micpath.2023.106356_bib34","first-page":"4539","article-title":"Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19","volume":"24","author":"Meo","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.micpath.2023.106356_bib35","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.2147\/DDDT.S164515","article-title":"Linezolid: a review of its properties, function, and use in critical care","volume":"12","author":"Hashemian","year":"2018","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.micpath.2023.106356_bib36","first-page":"99","article-title":"Linezolid resistance genes and genetic elements enhancing their dissemination in enterococci and streptococci","author":"Sadowy","year":"2018","journal-title":"Plasmid"},{"key":"10.1016\/j.micpath.2023.106356_bib37","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.riam.2009.06.003","article-title":"Amphotericin B: side effects and toxicity","volume":"26","author":"Laniado-Labor\u00edn","year":"2009","journal-title":"Rev. Iberoam. De. Micol."},{"key":"10.1016\/j.micpath.2023.106356_bib38","doi-asserted-by":"crossref","first-page":"459","DOI":"10.2174\/138920009788898019","article-title":"Amphotericin B and its new derivatives - mode of action","volume":"10","author":"Baginski","year":"2009","journal-title":"Curr. Drug Metabol."},{"key":"10.1016\/j.micpath.2023.106356_bib39","doi-asserted-by":"crossref","first-page":"655","DOI":"10.18388\/abp.2005_3426","article-title":"Molecular modelling of membrane activity of amphotericin B, a polyene macrolide antifungal antibiotic","volume":"52","author":"Baginski","year":"2005","journal-title":"Acta Biochim. Pol."},{"key":"10.1016\/j.micpath.2023.106356_bib40","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1345\/aph.19237","article-title":"Voriconazole: a new triazole antifungal","volume":"34","author":"Sabo","year":"2000","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.micpath.2023.106356_bib41","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1055\/s-0038-1626702","article-title":"Identification of fungal pathogens in otomycosis and their drug sensitivity: our experience","volume":"22","author":"Ali","year":"2018","journal-title":"Int. Arch. Otorhinolaryngol."},{"key":"10.1016\/j.micpath.2023.106356_bib42","series-title":"StatPearls","author":"Shutter","year":"2021"},{"key":"10.1016\/j.micpath.2023.106356_bib43","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.3390\/molecules25215064","article-title":"In vitro antiviral activity of doxycycline against SARS-CoV-2","volume":"25","author":"Gendrot","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.micpath.2023.106356_bib44","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1002\/jcb.29909","article-title":"Tetracycline as an inhibitor to the SARS-CoV-2","volume":"122","author":"Zhao","year":"2021","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.micpath.2023.106356_bib45","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jhin.2017.12.008","article-title":"Regional point prevalence study of healthcare-associated infections and antimicrobial use in acute care hospitals in Liguria, Italy","volume":"99","author":"Sticchi","year":"2018","journal-title":"J. Hosp. Infect."},{"key":"10.1016\/j.micpath.2023.106356_bib46","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1086\/510393","article-title":"Infectious diseases society of America and the society for healthcare epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship","volume":"44","author":"Dellit","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.micpath.2023.106356_bib47","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s10096-020-04063-8","article-title":"Rates of bacterial co-infections and antimicrobial use in COVID-19 patients: a retrospective cohort study in light of antibiotic stewardship","volume":"40","author":"Rothe","year":"2021","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.micpath.2023.106356_bib48","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11908-020-00734-x","article-title":"Antimicrobial stewardship at the core of COVID-19 response efforts: implications for sustaining and building programs","volume":"22","author":"Mazdeyasna","year":"2020","journal-title":"Curr. Infect. Dis. Rep."},{"key":"10.1016\/j.micpath.2023.106356_bib49","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1017\/ice.2020.69","article-title":"Involving antimicrobial stewardship programs in COVID-19 response efforts: all hands on deck","volume":"41","author":"Stevens","year":"2020","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"10.1016\/j.micpath.2023.106356_bib50","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/j.jinf.2020.06.056","article-title":"Improving antibiotic stewardship in COVID-19: bacterial co-infection is less common than with influenza","volume":"81","author":"Youngs","year":"2020","journal-title":"J. Infect."},{"key":"10.1016\/j.micpath.2023.106356_bib51","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of America and the American thoracic society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.micpath.2023.106356_bib52","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/cid\/cir301","article-title":"Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection","volume":"53","author":"Stevens","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.micpath.2023.106356_bib53","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2334-14-13","article-title":"A systematic review and meta-analysis of the effects of antibiotic consumption on antibiotic resistance","volume":"14","author":"Bell","year":"2014","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.micpath.2023.106356_bib54","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2165\/00003495-198427060-00001","article-title":"Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use","volume":"27","author":"Richards","year":"1984","journal-title":"Drugs"},{"key":"10.1016\/j.micpath.2023.106356_bib65","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.2147\/IDR.S299774","article-title":"Secondary infections in hospitalized COVID-19 patients: Indian experience","volume":"14","author":"Vijay","year":"2021","journal-title":"Infect. Drug Resist."},{"key":"10.1016\/j.micpath.2023.106356_bib55","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/j.1552-4604.1994.tb04733.x","article-title":"Pharmacokinetics of tazobactam M1 metabolite after administration of piperacillin\/tazobactam in subjects with renal impairment","volume":"34","author":"Halstenson","year":"1994","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.micpath.2023.106356_bib56","doi-asserted-by":"crossref","first-page":"19494","DOI":"10.1074\/jbc.M311669200","article-title":"Tazobactam inactivation of SHV-1 and the inhibitor-resistant Ser130 \u2192 gly SHV-1 \u03b2-lactamase: insights into the mechanism of inhibition","volume":"279","author":"Pagan-Rodriguez","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.micpath.2023.106356_bib57","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1086\/379328","article-title":"Fluoroquinolone resistance in patients with newly diagnosed tuberculosis","volume":"37","author":"Ginsburg","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.micpath.2023.106356_bib58","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1574-6968.1997.tb10321.x","article-title":"Molecular mechanisms of azole resistance in fungi","volume":"149","author":"Joseph-Horne","year":"1997","journal-title":"FEMS (Fed. Eur. Microbiol. Soc.) Microbiol. Lett."},{"key":"10.1016\/j.micpath.2023.106356_bib59","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1128\/AAC.01630-08","article-title":"Three-dimensional model of lanosterol 14\u03b1-demethylase from cryptococcus neoformans: active-site characterization and insights into azole binding","volume":"53","author":"Sheng","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2023.106356_bib60","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.2165\/00003495-200565140-00009","article-title":"Caspofungin","volume":"65","author":"McCormack","year":"2005","journal-title":"Drugs"},{"key":"10.1016\/j.micpath.2023.106356_bib61","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1586\/14787210.3.5.697","article-title":"Caspofungin: an overview","volume":"3","author":"Morrison","year":"2005","journal-title":"Expert Rev. Anti-infect. Ther."},{"key":"10.1016\/j.micpath.2023.106356_bib62","first-page":"79","article-title":"Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infections","volume":"9","author":"Donnelley","year":"2016","journal-title":"Infect. Drug Resist."},{"key":"10.1016\/j.micpath.2023.106356_bib63","first-page":"163","article-title":"Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections","volume":"6","author":"Falci","year":"2013","journal-title":"Infect. Drug Resist."},{"key":"10.1016\/j.micpath.2023.106356_bib66","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1056\/NEJMra0912273","article-title":"Nanomedicine","volume":"363","author":"Kim","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.micpath.2023.106356_bib67","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1007\/s12274-017-1858-y","article-title":"Nanoscale covalent organic polymers as a biodegradable nanomedicine for chemotherapy-enhanced photodynamic therapy of cancer","volume":"11","author":"Wang","year":"2018","journal-title":"Nano Res."},{"key":"10.1016\/j.micpath.2023.106356_bib68","doi-asserted-by":"crossref","first-page":"6569","DOI":"10.1039\/c3tb21238f","article-title":"Liposome-like nanostructures for drug delivery","volume":"1","author":"Gao","year":"2013","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.micpath.2023.106356_bib69","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00022","article-title":"Nanoparticle-based vaccines against respiratory viruses","author":"Al-Halifa","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.micpath.2023.106356_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120686","article-title":"Nasal vaccination against SARS-CoV-2: synergistic or alternative to intramuscular vaccines?","volume":"603","author":"Tiboni","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.micpath.2023.106356_bib64","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.cmi.2020.09.041","article-title":"Recommendations for antibacterial therapy in adults with COVID-19 \u2013 an evidence based guideline","volume":"27","author":"Sieswerda","year":"2021","journal-title":"Clin. Microbiol. Infection"},{"key":"10.1016\/j.micpath.2023.106356_bib71","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1021\/acscentsci.0c00272","article-title":"Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases","volume":"6","author":"Liu","year":"2020","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.micpath.2023.106356_bib72","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.colsurfb.2016.02.017","article-title":"Tea tree oil nanoemulsions for inhalation therapies of bacterial and fungal pneumonia","volume":"141","author":"Li","year":"2016","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.micpath.2023.106356_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.cocis.2021.101458","article-title":"Nanoemulsions: the rising star of antiviral therapeutics and nanodelivery system\u2014current status and prospects","volume":"54","author":"Franklyne","year":"2021","journal-title":"Curr. Opin. Colloid Interface Sci."},{"key":"10.1016\/j.micpath.2023.106356_bib74","doi-asserted-by":"crossref","first-page":"5570","DOI":"10.1021\/acs.nanolett.0c02278","article-title":"Cellular nanosponges inhibit SARS-CoV-2 infectivity","volume":"20","author":"Zhang","year":"2020","journal-title":"Nano Lett."},{"key":"10.1016\/j.micpath.2023.106356_bib75","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.3390\/molecules23092205","article-title":"Application of dendrimers for the treatment of infectious diseases","volume":"23","author":"Mhlwatika","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.micpath.2023.106356_bib76","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.3390\/pharmaceutics13091513","article-title":"Functionalized dendrimer platforms as a new forefront arsenal targeting SARS-CoV-2: an opportunity","volume":"13","author":"Mignani","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.micpath.2023.106356_bib77","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s11051-020-05010-6","article-title":"Pharmaceutical nanotechnology: which products are been designed against COVID-19?","volume":"22","author":"Cavalcanti","year":"2020","journal-title":"J. Nanoparticle Res."},{"key":"10.1016\/j.micpath.2023.106356_bib78","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.01328","article-title":"Advances in Nanoparticulate drug delivery approaches for sublingual and Buccal administration","volume":"10","author":"Hua","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.micpath.2023.106356_bib79","doi-asserted-by":"crossref","first-page":"7138","DOI":"10.1016\/j.biomaterials.2012.06.068","article-title":"A review of nanocarriers for the delivery of small interfering RNA","volume":"33","author":"Kesharwani","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.micpath.2023.106356_bib80","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3390\/biomedicines11020413","article-title":"Nanotechnology as a promising approach to combat multidrug resistant bacteria: a comprehensive review and future perspectives","volume":"11","author":"Hetta","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.micpath.2023.106356_bib81","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.3390\/cancers13143539","article-title":"Advanced Nanoparticle-based drug delivery systems and their cellular evaluation for non-small cell lung cancer treatment","volume":"13","author":"Mohtar","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.micpath.2023.106356_bib82","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s42247-021-00168-8","article-title":"Nanomedicine for COVID-19: the role of nanotechnology in the treatment and diagnosis of COVID-19","volume":"4","author":"Vahedifard","year":"2021","journal-title":"Emergent Mater"},{"key":"10.1016\/j.micpath.2023.106356_bib83","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.micpath.2023.106356_bib84","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1128\/mBio.01697-15","article-title":"Human coronavirus 229E remains infectious on common touch surface materials","volume":"6","author":"Warnes","year":"2015","journal-title":"mBio"}],"container-title":["Microbial Pathogenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0882401023003893?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0882401023003893?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:59:16Z","timestamp":1760111956000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0882401023003893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":84,"alternative-id":["S0882401023003893"],"URL":"https:\/\/doi.org\/10.1016\/j.micpath.2023.106356","relation":{},"ISSN":["0882-4010"],"issn-type":[{"value":"0882-4010","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibiotics and nano-antibiotics in treatment of lung infection: In management of COVID-19","name":"articletitle","label":"Article Title"},{"value":"Microbial Pathogenesis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.micpath.2023.106356","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106356"}}